GROWTH AND DEVELOPMENT



Similar documents
Antiretroviral therapy for HIV infection in infants and children: Towards universal access

Pediatric HIV - The World At It's Best

Routine HIV Monitoring

Objectives. What is undernutrition? What is undernutrition? What does undernutrition look like?

Chapter 21. What Are HIV and AIDS?

FEDERAL BUREAU OF PRISONS REPORT ON INFECTIOUS DISEASE MANAGEMENT

The Influence of Infant Health on Adult Chronic Disease

The Basics of Drug Resistance:

In Tanzania, ARVs were introduced free-of-charge by the government in 2004 and, by July 2008, almost 170,000 people were receiving the drugs.

TRACKS INFECTIOUS DISEASE EPIDEMIOLOGY

What is HIV? What is AIDS? The HIV pandemic HIV transmission Window period Stages of HIV infection

Viral load testing. medical monitoring: viral load testing: 1

FAQs HIV & AIDS. What is HIV? A virus that reduces the effectiveness of your immune system, meaning you are less protected against disease.

Weight-for-age percentiles: Girls 2-20 years Cerebral Palsy Group 1* (solid), General Population (dashed)

Transient Hypogammaglobulinemia of Infancy. Chapter 7

Pediatric Latent TB Diagnosis and Treatment

HBV screening and management in HIV-infected children and adolescents

The National Survey of Children s Health The Child

Overview of the CDC Growth Charts

Appendix E-- The CDC s Current and Proposed Classification System for HIV Infection

EMA and Progressive Multifocal Leukoencephalopathy.

Nutritional problems. Age-related diseases Functional impairments Drug-induced nutritional deficiencies

ICD-9-CM/ICD-10-CM Codes for MNT

NICHD s Pediatric, Adolescent, & Maternal AIDS Branch

Drug development for children: how adequate is the current European ethical guidance?

Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load

Key Facts about Influenza (Flu) & Flu Vaccine

Global Update on HIV Treatment 2013: Results, Impact and Opportunities

:58 FOR UK AND EMEA MEDICAL MEDIA ONLY. (Logo:

Ministero della Salute

A Guide for Hospitals and Health Care Providers Perinatal Substance Use: Promoting Healthy Outcomes

Early detection of HIV infection in infants and children

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press

CME Article Hiv Disease Surveillance

Hunger and Poverty: Definitions and Distinctions

SAVE A LIFE... BY GIVING LIFE!

Nutritional Risk Screening Tools in Hospitalised Children

Growth failure in HIV-infected children

Up to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data).

PERINATAL NUTRITION. Nutrition during pregnancy and lactation. Nutrition during infancy.

HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION

Hospitalizations for Hepatitis A, B, and C, Active Component, U.S. Armed Forces,

Orthopaedic Issues in Adults with CP: If I Knew Then, What I Know Now

How To Understand And Understand The Health Effects Of Hiv In Spain

Or download the manual from or

Cerebral palsy, neonatal death and stillbirth rates Victoria,

Child and Maternal Nutrition in Bangladesh

HIV/AIDS, Socioeconomic Status, and Life Insurance. The burden of being infected with the life-threatening disease HIV/AIDS

2013 Child Growth. Child growth and growth charts in the early years. Background

HIV/AIDS Care: The Diagnosis Code Series 2. Prepared By: Stacey L. Murphy, MPA, RHIA, CPC AHIMA Approved ICD-10-CM/ICD-10-CM Trainer

Guidance for Public Health Interventions for Repatriation

Severe Combined Immune Deficiency (SCID)

Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver

Asymptomatic HIV-associated Neurocognitive Disorder (ANI) Increases Risk for Future Symptomatic Decline: A CHARTER Longitudinal Study

Prior Authorization Form

HIV/AIDS POLICY STATEMENT

How To Kill Jesuva

Evidence-Based Practice for Public Health Identified Knowledge Domains of Public Health

A Gift for life. HTA Licence No

ELEMENTS FOR A PUBLIC SUMMARY. Overview of disease epidemiology. Summary of treatment benefits

Mid-year population estimates. Embargoed until: 20 July :30

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

Preconception care: Maximizing the gains for maternal and child health

Chapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections

Promoting Adherence to HIV Antiretroviral Therapy

Developmental delay and Cerebral palsy. Present the differential diagnosis of developmental delay.

The Liver and Alpha-1. Antitrypsin Deficiency (Alpha-1) 1 ALPHA-1 FOUNDATION

A Public Cord Blood Bank for South Africa? i

FAILURE TO THRIVE What Is Failure to Thrive?

3-1 THE NERVOUS SYSTEM

Liver means Life. Why this manifesto? We are eager to ensure. that we can contribute. to society as much. as possible, and we. are equally keen to

General and Abdominal Adiposity and Risk of Death in Europe

Objectives: Perform thorough assessment, and design and implement care plans on 12 or more seriously mentally ill addicted persons.

cambodia Maternal, Newborn AND Child Health and Nutrition

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum

Over 50% of hospitalized patients are malnourished. Coding for Malnutrition in the Adult Patient: What the Physician Needs to Know

Estimates of New HIV Infections in the United States

Genetic Testing in Research & Healthcare

Nutrition Promotion. Present Status, Activities and Interventions. 1. Control of Protein Energy Malnutrition (PEM)

UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE

Borderless Diseases By Sunny Thai

Frequently Asked Questions (FAQs)

Baskets of Care Diabetes Subcommittee

Referral Guidelines for TB/HIV co-management. (First Edition)

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015

Immunity and how vaccines work

Transcription:

Open Access Research Journal Medical and Health Science Journal, MHSJ www.pradec.eu ISSN: 1804-1884 (Print) 1805-5014 (Online) Volume 8, 2011, pp. 16-20 GROWTH AND DEVELOPMENT OF CHILDREN WITH HIV/AIDS There were observed 241 HIV-infected children. Indexes of children s physical development (PD) such as weight-to-growth, height-for-age, weight-for-age, and BMI-for-age were studied, depending on the age (less than 12 months, 12-35 and 36-59 month-old children), stage of disease, immunosuppression severity and HIV replication activity. It was revealed that PD indexes of children less than 12 months may not be used as predictors of HIV severity and progression rate. Adequate prognosis in regard of severity and progression rate according to PD indexes is possible only in children older than 1 year old. OLGA KIM Republican Specialized Scientific- Practical Medical Center of Pediatrics, Uzbekistan Keywords: Human immunodeficiency virus, acquired immunodeficiency syndrome, physical development, children. UDC: 616.98:578.828.6-053.2-07 Introduction Physical development (PD) is one of the main criteria of children s health. It has the value of objective criteria for individual organism s development due to relative simplicity and accessibility of research methods of children s PD, as well as the most information of materials obtained (Kapitonov, 2005). The fact that HIV infection in children results in significant disturbances of PD is well known (Berhane et al., 1997; McKinney et al., 1994; Miller, 2000). Accordingly, the more pronounced clinical signs of disease, the more clear symptoms of lag in PD (Moye et al., 1996). Saavedra et al. (1995) reported that children with AIDS lag in growth stronger than children in a less advanced stage of the disease. Berhane et al. (1997) observed that in Ugandan HIV-infected children weight loss followed by 5-fold increase in mortality, compared with the age norm (Z-index of less than 1.5). Saavedra et al. (1995) described a similar relationship between weight loss, disease progression and survival in the U.S.A. However, relationships between children s PD and other factors that influence on the progression of HIV infection (the level of viral RNA in plasma, immunodeficiency severity) are still not well studied. Thus, the main question Is it possible to rely on indicators of children s PD at estimation the risk of adverse outcome? remains poor understood. Thus, the purpose of our study was to investigate PD disturbances in HIV-infected children, depending on the viral replicative activity and immunodeficiency severity during the natural course of the disease. Materials and methods Objective of the study was 241 HIV-infected children. The children were divided into 3 groups according to age: I group - 19 children less than 12 months, II group - 107 children aged between 12-35 months, III group - 115 children aged between 36-59 months. We studied PD of HIV-infected children, depending on the stage of disease, immunosuppression severity and HIV replicative activity. Stage of HIV infection was determined according to the revised WHO clinical classification of HIV-infection in children (WHO, 2005), immunosuppression severity according to the WHO classification - 16 -

of HIV-associated immunodeficiency in children (Geneva, 2006). Empirical value of the level of HIV RNA in blood which is equal to 100.000 cop/ml was selected as the boundary separating HIV replicative activity. Anthropometric measurements and their evaluation were conducted according to the WHO Child Growth Standards (WHO, 2006a). Since the single anthropometric measurements (height or body weight) had limited values, we calculated such metrics as body weight for the given height (exhaustion), body length for the given age (stunting), body weight for the given age (integral index of physical development), as well estimated the ratio of body weight (in kg) to the body length in a prone position, or to the height in a standing position (in m 2 ) (body mass index-age) according to the WHO standard indicators of child s development (WHO, 2006b). Because the height or weight of children are very often were at the end of the distribution curve (e.g., below the 5th percentile), we used Z-index, which is a standardized measure to assess the relative growth rate or weight gain regardless of whether there are entry points of these indicators on the standard curve. A child with a height-age index, a measure of linear growth of more than two standard deviations (-2SD), was assessed as stunted, that reflecting a presence of chronic malnutrition. If the value of this indicator was more than three standard deviations (- 3SD), this state regarded as a severe growth retardation. A weight-growth index allowed assessing the nutritional status of child in the present. Children who had index values more than two standard deviations (-2SD) regarded as being underweight for growth and having a moderate degree of exhaustion. If a child was detected deviation of more than three standard deviations (3SD), his/her condition was regarded as a severe degree of exhaustion. An index weight-for-age was used as a good general indicator for the determination of nutrition status. Children who had values of more than two standard deviations (-2SD), were considered as having a moderate degree of malnutrition, whereas children with more than three standard deviations (3SD) were regarded to have a severe degree of malnutrition. The results obtained and discussion PD of children less than 12 months. In the separation of children less than 12 months by disease stages, no statistically significant difference was revealed. In the separation of this age group by HIV replicative activity statistically significant difference was found only when comparing the indicators of body mass index: in children with low HIV replicative activity ( 100.000 cop/ml) it was -2.31±0.66, whereas in children with viral load over 100.000 cop/ml it was -1.39±0.41 (p 0.05). Thus, in children less than 12 months viral load can not be used as a prognostic factor of unfavorable outcome. In the separation of children according to immunosuppression level, we obtained the discouraging results: the more severe the immunodeficiency, the PD indicators were closer to the norm. Absence of adequate correlation between the percentage of CD4 + lymphocytes and children s PD suggests that PD in any way can not serve as a predictor of immunodeficiency severity in HIV-infected children less than 12 months, as well as the level of CD4 + T-lymphocytes has no predictive value when assessing the risk of nutrition disorders in children. This is due to the immaturity of the immune system of early age children, resulting in even a fraction of CD4+ lymphocytes does not reflect the true picture of the formation of the adaptive immune response. Thus, in children less than 12 months, PD does not reflect the severity of disease, as well as there was no dependence on the level of replicative activity and immunodeficiency severity. The abovementioned means that in children less than 12 months the prediction of risk of adverse disease course is not possible in terms of immunodeficiency level and - 17 -

viral load, because even such a sensitive sign as PD does not response to changes in the immunological status of patient and viral replicative activity. PD of 12-35 month-old children. In children aged between 12-35 months, disease progression was accompanied by more serious PD disturbances. The separation by HIV replicative activity also showed that children with high replicative activity had more pronounced delay in linear growth and malnutrition than the children controlling virus replication (Table 1). TABLE 1. DISTURBANCES IN CHILDREN S PHYSICAL DEVELOPMENT, DEPENDING ON THE DISEASE STAGE AND HIV REPLICATIVE ACTIVITY Indicator Stage III Stage IV Weight-to-growth (z) -0.33±0.28-2.08±0.23*** Height-for-age (z) -1.5±0.42-1.8±0.27 Weight-for-age (z) -1.05±0.24-2.52±0.16*** BMI-for-age (z) -0.12±0.32-1.92±0.6*** Index 100 000 cop/ml > 100 000 cop/ml Weight-to-growth (z) -1.51±0.64-1.74±0.31 Height-for-age (z) -0.22±0.92-1.85±0.38* Weight-for-age (z) -1.22±0.45-2.25±0.26* BMI-for-age (z) -1.49±0.75-1.53±0.35 Note: * - significant differences between comparing groups. Thus, we can see a close relationship between child s PD state and disease progression, which is bilateral in nature: HIV infection modifies the nutritional status of the child as a result of malabsorption, increased nutrient requirements and metabolic disorders, especially against opportunistic and other infections, whereas nutrient deficiency, in its turn, leads to the disease progression. The separation by immunosuppression severity reflected the natural course of HIV infection, in which with disease progression worsening of signs of exhaustion and malnutrition were marked, that was confirmed by statistical significance (Table 2). TABLE 2. DISTURBANCES IN CHILDREN S PHYSICAL DEVELOPMENT, DEPENDING ON IMMUNODEFICIENCY LEVEL Index Mild Moderate Pronounced Severe Weight-to-growth (z) -1.53±0.64-0.77±0.53-1.54±0.28-2.28±0.34^^# Height-for-age (z) -1.09±0.52-1.04±0.72-1.98±0.43-2.04±0.4^ Weight-for-age (z) -1.71±0.49-1.41±0.36-2.15±0.26^ -2.74±0.22*^^^# BMI-for-age (z) -1.33±0.68-0.94±0.67-1.3±0.32-2.06±0.4^ Notes: * - reliability between indexes of children with mild immunodeficiency; ^ - reliability between indexes of children with moderate immunodeficiency; # - reliability between indexes of children with pronounced immunodeficiency PD of 36-59 month-old children. In children in this age group we revealed the dependence of PD indicators on disease progression, which is statistically reflected by all anthropometric indicators. The separation by replicative activity has demonstrated once again how child s nutrition status is very sensitive to increase of HIV level in child s organism (Table 3). - 18 -

TABLE 3. DISTURBANCES IN CHILDREN S PHYSICAL DEVELOPMENT, DEPENDING ON THE DISEASE STAGE AND HIV REPLICATIVE ACTIVITY Indicator Stage III Stage IV Weight-to-growth (z) 0.29±0.17-1.16±0.28*** Height-for-age (z) -1.57±0.16-2.54±0.25*** Weight-for-age (z) -0.75±0.14-2.27±0.22*** BMI-for-age (z) 0.43±0.17-0.9±0.29*** Index 100 000 cop/ml > 100 000 cop/ml Weight-to-growth (z) 0.19±0.29-0.97±0.34** Height-for-age (z) -1.31±0.26-2.23±0.36* Weight-for-age (z) -0.66±0.23-1.98±0.33** BMI-for-age (z) 0.3±0.31-0.72±0.35* Note: * - significant differences between comparing groups Adequate reflection of the natural course of disease was obtained also after separation by immunosuppression severity. In this case, the worsening of immunodeficiency leads to rough deviation of PD indicators (Table 4). TABLE 4. DISTURBANCES IN CHILDREN S PHYSICAL DEVELOPMENT, DEPENDING ON IMMUNODEFICIENCY LEVEL Index Mild Moderate Pronounced Severe Weight-to-growth (z) 0.29±0.24-0.74±0.38* -0.26±0.39-1.07±0.43** Height-for-age (z) -1.86±0.19-1.42±0.29-2.04±0.33-2.36±0.43 Weight-for-age (z) -0.89±0.21-1.33±0.31-1.42±0.37-2.12±0.37** BMI-for-age (z) 0.48±0.23-0.6±0.39* -0.08±0.38-0.84±0.44** Note: * - moderate/insignificant and severe/insignificant differences between comparing groups Thus, in children of 36-59 months, disease stage, severity of immunosuppression and viral load are highly significant predictors in assessment the risk of adverse outcome, like in children of 12-35 months. However, according to our study, PD indicators of HIVinfected children, whose measurement is more accessible in resource-limited settings, can testify to disease progression at early stages. Conclusion The results of our study are very valuable, as they prove the use of PD indicators to determine the risk of adverse outcome (e.g., lethality, deterioration of patient s health, absent or unsatisfactory dynamics in treatment course), especially in countries with limited resources, lack of access to routine implementation of immunological and virological tests. However, for children less than 12 months we recommend frequent examination involving all the specialized expertise to maximize the early detection of signs of disease progression and timely administration of antiretroviral therapy, because children in this age group had no significant predictive signs of risk for adverse outcome. The abovementioned makes it possible to do the following conclusions: PD indicators of children less than 12 months may not be used as predictors of HIV severity and progression rate. Adequate prognosis in regard of severity and progression rate according to PD indicators is possible only in children older than 1 year old. PD monitoring in children older than 1 year old will allow using not only its predictive possibility, but also control the effectiveness of antiretroviral therapy, along with the - 19 -

monitoring of blood viral RNA and the levels of CD4+ T-lymphocytes, especially in developing countries which have no access to routine implementation of immunological and virological tests. References Berhane, R., Bagenda, D., Marum, L. et al., 1997. Growth failure as a prognostic indicator of mortality in pediatric HIV infection, J. Pediatrics, Vol.100, p.e7 Kapitonov, V., 2005. Genetic approach in evaluating the growth characteristics and child s development, Pediatrics [Pediatriya], in Russian, No.3, pp.58-60 McKinney, R., Wilfert, C., 1994. Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine. AIDS Clinical Trials Group Protocol 043 Study Group, J. Pediatrics, Vol.125, pp.728-33 Miller, T., 2000. Nutrition in paediatric human immunodeficiency virus infection, Proc. Nutr. Soc., Vol.59, pp.155-162 Moye, J., Rich, K., Kalish, L., et al., 1996. Natural history of somatic growth in infants born to women infected by human immunodeficiency virus, J. Pediatrics, Vol.128, pp.58-67 Saavedra, J., Henderson, R., Perman, J., Hutton, N., Livingston, R., Yolken, R., 1995. Longitudinal assessment of growth in children born to mothers with human immunodeficiency virus infection, Arch. Pediatr. Adolesc. Med., Vol.149, pp.497-502 WHO, 2005. Report of the technical consultation on clinical staging of HIV/AIDS and HIV/AIDS case definition for surveillance, Copenhagen, WHO Regional Office for Europe WHO, 2006a. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings, WHO Child Growth Standards, towards universal access: Recommendation of a public health approach, Geneva WHO, 2006b. Standard indicators of child s development (length / height-age, weight-for-age, body massbody length, body weight, height and body mass index, age): Methods and developments, in Russian - 20 -